Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Sodium nitrite (Primary)
- Indications Kidney disorders
- Focus Pharmacodynamics
- Acronyms NICE
- 11 Aug 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2016 Protocol amended as dose of Isoquercetin changed from 250 mg to 225 mg, Vitamin C has been removed from treatments and dosage form changed from sustained to immediate release, as reported by ClinicalTrials.gov record.